Q2 FY2026 EarningsQ2 FY26 results beat consensus across the board, with revenue of $85.7M exceeding the $85.5M expected and diluted GAAP EPS of $0.34 significantly outperforming the $0.14 mean estimate. Gross margin expanded to 76.0% (vs. 75.4% expected), driven by lymphedema product sales (+12% YoY), though airway clearance revenue declined 7% due to temporary inventory management. Despite the bottom-line beat, management lowered the upper end of FY26 revenue guidance to $360M-$366M (previously $368M), citing conservative ordering patterns for the AffloVest launch.
Financial report interval: 2026.03.30 - 2026.06.30
Preview: Tactile(TCMD) predict that the Revenue is 85.7 M (+8.61%), Beat estimate;the EBIT is 6.826 M (+67.18%), Beat estimate;the EPS is 0.34 (+142.9%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.09B8.61%
0.09B8.39%
+0.00B0.22%
EBITExceed expectations
0.01B67.18%
0.00B4.92%
+0.00B72.10%
EPSExceed expectations
0.34142.86%
0.1442.86%
+0.1960140.00%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf